EyeGate Pharma, the leader in non-invasive ocular drug delivery, announces that they have established a research collaboration with GlaxoSmithKline (GSK) to evaluate the delivery of several GSK therapies to the anterior (front) and posterior (back) tissues of the eye using the EyeGate II delivery system. Specific terms of the agreement were not disclosed. 

Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, “EyeGate has developed a unique, non-invasive system that delivers therapeutics for ocular diseases. Our research collaboration with GlaxoSmithKline seeks to demonstrate the ability of EyeGate’s proprietary technology in delivering GSK molecules targeted to areas of the eye.”

Currently available ocular drug delivery options, which include topical drops and intravitreal injections, have limitations and associated risks. Ophthalmic drops are poorly absorbed into ocular tissues and can result in significant systemic concentrations. Intravitreal injections can lead to hemorrhaging, retinal detachment, endophalmitis, and other complications. To address the need for improved ocular drug delivery, EyeGate Pharma has developed a novel, non-invasive device that uses low-level electrical current to deliver drug substances to targeted areas of the eye. 

EyeGate is the first company to conduct multiple controlled clinical trials to assess the safety and efficacy of iontophoresis technology to deliver therapeutics into the eye. EyeGate has successfully completed two Phase II studies of EGP-437, a corticosteroid solution administered by the EyeGate II delivery system: one in dry eye syndrome (DES) patients and one in anterior uveitis patients.

Date: April 29, 2010
Source: EyeGate Pharma